p53 Activation by small molecules: application in oncology

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.

Journal of medicinal chemistry·2023

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.

Molecular cancer therapeutics·2023

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death.

Aging·2023

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

Molecular cancer therapeutics·2022

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.

Molecular cancer research : MCR·2022

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.

Scientific reports·2021

Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers.

Journal of medicinal chemistry·2026

Structure-Guided Discovery of Novel Dual-Site FEM1B Ligands and Assessment of Their Use in Targeted Protein Degradation.

Journal of medicinal chemistry·2026

Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors.

Journal of medicinal chemistry·2026

Circular Bivalent Aptamer Chimeras Leveraging LDLR-Mediated Lysosomal Shuttling for Targeted Protein Degradation.

Journal of medicinal chemistry·2026

The Mycobacterial cyt-bc1:aac3 Oxidase as a Drug Target: Activities of Arylvinylpiperazine Amides and Aminoquinazolines against Mycobacterium ulcerans.

Journal of medicinal chemistry·2026

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Journal of medicinal chemistry·2026

Cuproptosis-related Gene SLC31A1 Correlates with M2 Macrophage Infiltration and Serves as a Potential Therapeutic Target in Glioma: A Comprehensive Analysis of 1573 Samples from TCGA and CGGA Databases.

Recent patents on anti-cancer drug discovery·2026

Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials.

Journal of biopharmaceutical statistics·2026

Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.

Molecular therapy. Advances·2026

Longitudinal drug response assessment of tumor organoids based on optical attenuation coefficient and multi-dimensional morphological characterization.

Biomedical optics express·2026

Nanosensitive optical coherence tomography to monitor corneal burn and treatment response in vivo.

Biomedical optics express·2026

Contemporary perspectives on metabolic surgery for type 2 diabetes: surgical techniques, outcomes, and complications.

Frontiers in endocrinology·2026

Related Experiment Videos

p53 Activation by small molecules: application in oncology

Related Concept Videos

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death.

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.

Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers.

Structure-Guided Discovery of Novel Dual-Site FEM1B Ligands and Assessment of Their Use in Targeted Protein Degradation.

Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors.

Circular Bivalent Aptamer Chimeras Leveraging LDLR-Mediated Lysosomal Shuttling for Targeted Protein Degradation.

The Mycobacterial cyt-<i>bc</i><sub>1</sub><i>:aac<sub>3</sub></i> Oxidase as a Drug Target: Activities of Arylvinylpiperazine Amides and Aminoquinazolines against <i>Mycobacterium ulcerans</i>.

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Cuproptosis-related Gene SLC31A1 Correlates with M2 Macrophage Infiltration and Serves as a Potential Therapeutic Target in Glioma: A Comprehensive Analysis of 1573 Samples from TCGA and CGGA Databases.

Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials.

Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.

Longitudinal drug response assessment of tumor organoids based on optical attenuation coefficient and multi-dimensional morphological characterization.

Nanosensitive optical coherence tomography to monitor corneal burn and treatment response in vivo.

Contemporary perspectives on metabolic surgery for type 2 diabetes: surgical techniques, outcomes, and complications.

Related Experiment Videos

p53 Activation by small molecules: application in oncology

Related Concept Videos

Related Articles